Literature DB >> 19619958

Stereotactic radiosurgery in the management of brain metastases: an institutional retrospective analysis of survival.

James L Frazier1, Sachin Batra, Sumit Kapor, Ananth Vellimana, Rahul Gandhi, Kathryn A Carson, Ori Shokek, Michael Lim, Lawrence Kleinberg, Daniele Rigamonti.   

Abstract

PURPOSE: The objective of this study was to report our experience with stereotactic radiosurgery performed with the Gamma Knife (GK) in the treatment of patients with brain metastases and to compare survival for those treated with radiosurgery alone with survival for those treated with radiosurgery and whole-brain radiotherapy. METHODS AND MATERIALS: Prospectively collected demographic and clinical characteristics and treatment and survival data on 237 patients with intracranial metastases who underwent radiosurgery with the GK between 2003 and 2007 were reviewed. Kaplan-Meier and Cox proportional hazards regression analyses were used to compare survival by demographic and clinical characteristics and treatment.
RESULTS: The mean age of the patient population was 56 years. The most common tumor histologies were non-small-cell lung carcinoma (34.2%) and breast cancer (13.9%). The median overall survival time was 8.5 months from the time of treatment. The median survival times for patients with one, two/three, and four or more brain metastases were 8.5, 9.4, and 6.7 months, respectively. Patients aged 65 years or greater and those aged less than 65 years had median survival times of 7.8 and 9 months, respectively (p = 0.008). The Karnofsky Performance Score (KPS) at the time of treatment was a significant predictor of survival: those patients with a KPS of 70 or less had a median survival of 2.9 months compared with 10.3 months (p = 0.034) for those with a KPS of 80 or greater. There was no statistically significant difference in survival between patients treated with radiosurgery alone and those treated with radiosurgery plus whole-brain radiotherapy.
CONCLUSIONS: Radiosurgery with the GK is an efficacious treatment modality for brain metastases. A KPS greater than 70, histology of breast cancer, smaller tumor volume, and age less than 65 years were associated with a longer median survival in our study.

Entities:  

Mesh:

Year:  2009        PMID: 19619958     DOI: 10.1016/j.ijrobp.2009.03.028

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  20 in total

1.  The cost-effectiveness of surgical resection and cesium-131 intraoperative brachytherapy versus surgical resection and stereotactic radiosurgery in the treatment of metastatic brain tumors.

Authors:  A Gabriella Wernicke; Menachem Z Yondorf; Bhupesh Parashar; Dattatreyudu Nori; K S Clifford Chao; John A Boockvar; Susan Pannullo; Philip Stieg; Theodore H Schwartz
Journal:  J Neurooncol       Date:  2016-01-02       Impact factor: 4.130

2.  Identifying better surgical candidates among recursive partitioning analysis class 2 patients who underwent surgery for intracranial metastases.

Authors:  Kaisorn L Chaichana; Shami Acharya; Mariana Flores; Olindi Wijesekera; Daniele Rigamonti; Jon D Weingart; Alessandro Olivi; Chetan Bettegowda; Gary L Gallia; Henry Brem; Michael Lim; Alfredo Quinones-Hinojosa
Journal:  World Neurosurg       Date:  2013-09-25       Impact factor: 2.104

3.  Predictors of inpatient death and complications among postoperative elderly patients with metastatic brain tumors.

Authors:  Rachel Grossman; Debraj Mukherjee; David C Chang; Michael Purtell; Michael Lim; Henry Brem; Alfredo Quiñones-Hinojosa
Journal:  Ann Surg Oncol       Date:  2010-08-31       Impact factor: 5.344

4.  Poor performance status and brain metastases treatment: who may benefit from the stereotactic radiotherapy?

Authors:  Katarzyna Holub; Guillaume Louvel
Journal:  J Neurooncol       Date:  2021-02-15       Impact factor: 4.130

5.  Complications of Radiotherapy and Radiosurgery in the Brain and Spine.

Authors:  G Barisano; S Bergamaschi; J Acharya; A Rajamohan; W Gibbs; P Kim; G Zada; E Chang; M Law
Journal:  Neurographics (2011)       Date:  2018-06

6.  Survival and recurrence for patients undergoing surgery of skull base intracranial metastases.

Authors:  Kaisorn L Chaichana; Mariana Flores; Shami Acharya; Paul Sampognaro; Chetan Bettegowda; Daniele Rigamonti; Jon D Weingart; Alessandro Olivi; Gary L Gallia; Henry Brem; Michael Lim; Alfredo Quinones-Hinojosa
Journal:  J Neurol Surg B Skull Base       Date:  2013-04-03

7.  Repeated stereotactic radiosurgery for patients with progressive brain metastases.

Authors:  Giuseppe Minniti; Claudia Scaringi; Sergio Paolini; Enrico Clarke; Francesco Cicone; Vincenzo Esposito; Andrea Romano; Mattia Osti; Riccardo Maurizi Enrici
Journal:  J Neurooncol       Date:  2015-09-14       Impact factor: 4.130

8.  Fifty percent patients avoid whole brain radiotherapy: stereotactic radiotherapy for multiple brain metastases: a retrospective analysis of a single center.

Authors:  Xiujun Chen; Jianping Xiao; Xiangpan Li; Xuesong Jiang; Ye Zhang; Yingjie Xu; Jianrong Dai
Journal:  Clin Transl Oncol       Date:  2012-07-19       Impact factor: 3.405

9.  CyberKnife Stereotactic Radiosurgery in brain metastases: A report from Latin America with literature review.

Authors:  Cuauhtémoc de la Peña; Jorge H Guajardo; María F Gonzalez; César González; Benjamín Cruz
Journal:  Rep Pract Oncol Radiother       Date:  2018-03-18

10.  Radiation as an immunological adjuvant: current evidence on dose and fractionation.

Authors:  Sandra Demaria; Silvia C Formenti
Journal:  Front Oncol       Date:  2012-10-26       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.